Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial

NCT02330406 is registered in ClinicalTrials.gov with Institute for Clinical Effectiveness, Japan as lead sponsor.

NCT NCT02330406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02330406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial
Lead sponsor
Institute for Clinical Effectiveness, Japan
Phase
Phase 4
Overall status
Completed
Start date
April 30, 2015
Completion date
March 31, 2019
Enrollment
353 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronary disease, diabetes mellitus, dipeptidyl-peptidase 4 inhibitors, glycosylated hemoglobin, ldl cholesterol